Nathan K Leclair1, Erica Shen2,3, Qian Wu4, Leo Wolansky5, Kevin Becker6, Lei Li3, Ketan R Bulsara7. 1. School of Medicine, University of Connecticut, 263 Farmington Ave, Farmington, CT, 06030, USA. 2. Division of Neurosurgery, Department of Surgery, UConn Health, 263 Farmington Ave, Farmington, CT, 06030, USA. 3. The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT, 06030, USA. 4. Department of Pathology and Laboratory Medicine, UConn Health, 263 Farmington Ave, Farmington, CT, 06030, USA. 5. Department of Radiology, UConn Health, 263 Farmington Ave, Farmington, CT, 06030, USA. 6. Department of Oncology, UConn Health, 263 Farmington Ave, Farmington, CT, 06030, USA. 7. Division of Neurosurgery, Department of Surgery, UConn Health, 263 Farmington Ave, Farmington, CT, 06030, USA. bulsara@uchc.edu.
Abstract
BACKGROUND: Meningiomas are the most common primary central nervous system tumor. Previous studies have characterized recurrent genetic alterations that can predict patient prognosis and potentially provide new avenues for therapeutic intervention. Continued efforts to characterize the genomic changes in meningioma samples can aid in the discovery of therapeutic targets and appropriate patient stratification. METHODS: We performed targeted genomic sequencing on 25 primary and 2 recurrent meningiomas using a 500-gene panel, including canonical meningioma drivers. We further detail the genomic profiles and relevant clinical findings in three cases of angiomatous meningiomas and two recurrent atypical meningiomas. RESULTS: Our approach uncovers a diverse landscape of genomic variants in meningioma samples including mutations in established meningioma-related genes NF2, AKT1, PIK3CA, and TRAF7. In addition to known meningioma drivers, we uncover variants in genes encoding other PI3K subunits, Notch/hedgehog/Wnt signaling pathway components, and chromatin regulators. We additionally identify 22 genes mutated across multiple samples. Three patients included in the study were diagnosed with angiomatous WHO grade I meningiomas, all three of which contained variants in the PI3K-AKT signaling pathway previously described to regulate tumor angiogenesis. Analysis of patient-matched primary and recurrent atypical meningiomas revealed clonal enrichment for mutations in the SWI/SNF complex subunits ARID1A and SMARCA4. CONCLUSIONS: Targeted genomics implemented in neuro-oncology care can enhance our understanding of the genetic underpinnings of central nervous system tumors, including meningiomas. These molecular signatures may be clinically useful in dictating treatment strategies and patient follow-up.
BACKGROUND: Meningiomas are the most common primary central nervous system tumor. Previous studies have characterized recurrent genetic alterations that can predict patient prognosis and potentially provide new avenues for therapeutic intervention. Continued efforts to characterize the genomic changes in meningioma samples can aid in the discovery of therapeutic targets and appropriate patient stratification. METHODS: We performed targeted genomic sequencing on 25 primary and 2 recurrent meningiomas using a 500-gene panel, including canonical meningioma drivers. We further detail the genomic profiles and relevant clinical findings in three cases of angiomatous meningiomas and two recurrent atypical meningiomas. RESULTS: Our approach uncovers a diverse landscape of genomic variants in meningioma samples including mutations in established meningioma-related genes NF2, AKT1, PIK3CA, and TRAF7. In addition to known meningioma drivers, we uncover variants in genes encoding other PI3K subunits, Notch/hedgehog/Wnt signaling pathway components, and chromatin regulators. We additionally identify 22 genes mutated across multiple samples. Three patients included in the study were diagnosed with angiomatous WHO grade I meningiomas, all three of which contained variants in the PI3K-AKT signaling pathway previously described to regulate tumor angiogenesis. Analysis of patient-matched primary and recurrent atypical meningiomas revealed clonal enrichment for mutations in the SWI/SNF complex subunits ARID1A and SMARCA4. CONCLUSIONS: Targeted genomics implemented in neuro-oncology care can enhance our understanding of the genetic underpinnings of central nervous system tumors, including meningiomas. These molecular signatures may be clinically useful in dictating treatment strategies and patient follow-up.
Authors: Malak S Abedalthagafi; Wenya Linda Bi; Parker H Merrill; William J Gibson; Matthew F Rose; Ziming Du; Joshua M Francis; Rose Du; Ian F Dunn; Azra H Ligon; Rameen Beroukhim; Sandro Santagata Journal: Cancer Genet Date: 2015-03-18
Authors: Victoria E Clark; E Zeynep Erson-Omay; Akdes Serin; Jun Yin; Justin Cotney; Koray Ozduman; Timuçin Avşar; Jie Li; Phillip B Murray; Octavian Henegariu; Saliha Yilmaz; Jennifer Moliterno Günel; Geneive Carrión-Grant; Baran Yilmaz; Conor Grady; Bahattin Tanrikulu; Mehmet Bakircioğlu; Hande Kaymakçalan; Ahmet Okay Caglayan; Leman Sencar; Emre Ceyhun; A Fatih Atik; Yaşar Bayri; Hanwen Bai; Luis E Kolb; Ryan M Hebert; S Bulent Omay; Ketu Mishra-Gorur; Murim Choi; John D Overton; Eric C Holland; Shrikant Mane; Matthew W State; Kaya Bilgüvar; Joachim M Baehring; Philip H Gutin; Joseph M Piepmeier; Alexander Vortmeyer; Cameron W Brennan; M Necmettin Pamir; Türker Kiliç; Richard P Lifton; James P Noonan; Katsuhito Yasuno; Murat Günel Journal: Science Date: 2013-01-24 Impact factor: 47.728
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Malak Abedalthagafi; Wenya Linda Bi; Ayal A Aizer; Parker H Merrill; Ryan Brewster; Pankaj K Agarwalla; Marc L Listewnik; Dora Dias-Santagata; Aaron R Thorner; Paul Van Hummelen; Priscilla K Brastianos; David A Reardon; Patrick Y Wen; Ossama Al-Mefty; Shakti H Ramkissoon; Rebecca D Folkerth; Keith L Ligon; Azra H Ligon; Brian M Alexander; Ian F Dunn; Rameen Beroukhim; Sandro Santagata Journal: Neuro Oncol Date: 2016-01-28 Impact factor: 12.300
Authors: Malak S Abedalthagafi; Parker H Merrill; Wenya Linda Bi; Robert T Jones; Marc L Listewnik; Shakti H Ramkissoon; Aaron R Thorner; Ian F Dunn; Rameen Beroukhim; Brian M Alexander; Priscilla K Brastianos; Joshua M Francis; Rebecca D Folkerth; Keith L Ligon; Paul Van Hummelen; Azra H Ligon; Sandro Santagata Journal: Oncotarget Date: 2014-11-15
Authors: Roberta L Beauchamp; Marianne F James; Patrick A DeSouza; Vilas Wagh; Wen-Ning Zhao; Justin T Jordan; Anat Stemmer-Rachamimov; Scott R Plotkin; James F Gusella; Stephen J Haggarty; Vijaya Ramesh Journal: Oncotarget Date: 2015-07-10
Authors: Priscilla K Brastianos; Peleg M Horowitz; Sandro Santagata; Robert T Jones; Aaron McKenna; Gad Getz; Keith L Ligon; Emanuele Palescandolo; Paul Van Hummelen; Matthew D Ducar; Alina Raza; Ashwini Sunkavalli; Laura E Macconaill; Anat O Stemmer-Rachamimov; David N Louis; William C Hahn; Ian F Dunn; Rameen Beroukhim Journal: Nat Genet Date: 2013-01-20 Impact factor: 38.330